ZA200803527B - Crystals of laquinimod sodium, and process for the manufacture thereof - Google Patents

Crystals of laquinimod sodium, and process for the manufacture thereof

Info

Publication number
ZA200803527B
ZA200803527B ZA200803527A ZA200803527A ZA200803527B ZA 200803527 B ZA200803527 B ZA 200803527B ZA 200803527 A ZA200803527 A ZA 200803527A ZA 200803527 A ZA200803527 A ZA 200803527A ZA 200803527 B ZA200803527 B ZA 200803527B
Authority
ZA
South Africa
Prior art keywords
crystals
manufacture
laquinimod sodium
laquinimod
sodium
Prior art date
Application number
ZA200803527A
Other languages
English (en)
Inventor
Frenkel Anton
Gurevich Eduard
Laxer Avital
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA200803527B publication Critical patent/ZA200803527B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
ZA200803527A 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof ZA200803527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72865705P 2005-10-19 2005-10-19

Publications (1)

Publication Number Publication Date
ZA200803527B true ZA200803527B (en) 2009-09-30

Family

ID=37963287

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803527A ZA200803527B (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof

Country Status (24)

Country Link
US (4) US7884208B2 (he)
EP (2) EP1937642B1 (he)
JP (3) JP5832716B2 (he)
KR (1) KR101440982B1 (he)
CN (3) CN107176923A (he)
AR (1) AR056708A1 (he)
AU (1) AU2006304672B2 (he)
BR (1) BRPI0617477A2 (he)
CA (1) CA2625287C (he)
DK (1) DK1937642T3 (he)
ES (1) ES2523762T3 (he)
HK (1) HK1117160A1 (he)
HR (1) HRP20141160T1 (he)
IL (1) IL190137A (he)
NZ (2) NZ592897A (he)
PL (1) PL1937642T3 (he)
PT (1) PT1937642E (he)
RS (1) RS53666B1 (he)
RU (1) RU2415841C2 (he)
SG (1) SG10201508623RA (he)
SI (1) SI1937642T1 (he)
UA (1) UA92761C2 (he)
WO (1) WO2007047863A2 (he)
ZA (1) ZA200803527B (he)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
NZ592897A (en) * 2005-10-19 2012-12-21 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EP2318371A2 (en) 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
US20120009226A1 (en) 2008-12-17 2012-01-12 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
PL2442651T3 (pl) 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
CN102480960A (zh) * 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EP2542079B1 (en) * 2010-03-03 2014-05-21 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
BR112012021905A2 (pt) * 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
WO2011109536A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
AR082150A1 (es) 2010-07-09 2012-11-14 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
EP3056205A1 (en) 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
AU2011333346A1 (en) 2010-11-28 2013-05-30 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
CN103974704A (zh) * 2011-10-12 2014-08-06 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
EP2894619A4 (en) 2012-09-03 2016-03-16 Toyota Motor Co Ltd DEVICE AND METHOD FOR COLLISION DETERMINATION
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
EP2968203A1 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
PE20160945A1 (es) 2013-11-15 2016-09-26 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613574A (en) * 1898-11-01 Feed-regulator
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6256814B1 (en) 1997-09-19 2001-07-10 Cosco Management, Inc. Playyard
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
KR100833633B1 (ko) 1999-06-07 2008-05-30 니코메드 게엠베하 산에 불안정한 활성 화합물을 포함하는 신규 제제 및 투여형태
US6395750B1 (en) * 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
NZ592897A (en) 2005-10-19 2012-12-21 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EP2318371A2 (en) 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
NZ591315A (en) 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
PL2442651T3 (pl) 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
CN102480960A (zh) 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
WO2011109536A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
EP2542079B1 (en) 2010-03-03 2014-05-21 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
EP3056205A1 (en) 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
AR082150A1 (es) 2010-07-09 2012-11-14 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
US20120055072A1 (en) * 2010-09-08 2012-03-08 Rankin Sammy D Directional guide for fishing lures
AU2011338647A1 (en) 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
JP5832716B2 (ja) 2015-12-16
DK1937642T3 (en) 2014-12-15
EP1937642A4 (en) 2009-03-18
IL190137A0 (en) 2008-08-07
IL190137A (he) 2015-06-30
AU2006304672B2 (en) 2013-01-10
HK1117160A1 (en) 2009-01-09
US7884208B2 (en) 2011-02-08
UA92761C2 (ru) 2010-12-10
KR101440982B1 (ko) 2014-09-17
HRP20141160T1 (hr) 2015-01-16
EP1937642B1 (en) 2014-09-10
US20110118308A1 (en) 2011-05-19
US20110112141A1 (en) 2011-05-12
SI1937642T1 (sl) 2015-01-30
CA2625287C (en) 2016-07-26
EP2687512A1 (en) 2014-01-22
CN101291911B (zh) 2014-08-13
CA2625287A1 (en) 2007-04-26
RU2008119456A (ru) 2009-11-27
BRPI0617477A2 (pt) 2011-07-26
WO2007047863A3 (en) 2007-06-28
US20070088050A1 (en) 2007-04-19
KR20080064978A (ko) 2008-07-10
SG10201508623RA (en) 2015-11-27
NZ592897A (en) 2012-12-21
JP2016020353A (ja) 2016-02-04
JP2009512708A (ja) 2009-03-26
CN107176923A (zh) 2017-09-19
JP2013100299A (ja) 2013-05-23
US8647646B2 (en) 2014-02-11
PT1937642E (pt) 2014-11-25
RS53666B1 (en) 2015-04-30
US8673322B2 (en) 2014-03-18
ES2523762T3 (es) 2014-12-01
CN101291911A (zh) 2008-10-22
NZ567088A (en) 2012-06-29
WO2007047863A2 (en) 2007-04-26
PL1937642T3 (pl) 2015-02-27
AU2006304672A1 (en) 2007-04-26
RU2415841C2 (ru) 2011-04-10
US20140171647A1 (en) 2014-06-19
EP1937642A2 (en) 2008-07-02
AR056708A1 (es) 2007-10-17
CN103333107A (zh) 2013-10-02

Similar Documents

Publication Publication Date Title
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
IL192241A (he) תהליך להכנת 4–(בנזימידאזולילימתילאמינו)–בנזאמידים ומלחיהם
EP1925617A4 (en) Heterocyclic compound, method of preparation and use
PL1844036T3 (pl) Sposób otrzymywania arypiprazolu
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
ZA200710914B (en) Process for the preparation of sulfonamide derivatives
EP1867623A4 (en) Terephthalic derivatives, tetrahalothiophenyl derivatives and processes for their preparation
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
ZA200601910B (en) Process for the preparation of organosilances
PL1763508T3 (pl) Sposób wytwarzania mocznika
GB0713385D0 (en) Process for the preparation of pantoprazole sodium
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
PL1753720T3 (pl) Proces wytwarzania peryndoprylu i jego soli
EP1968942A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF SODIUM MONTELUKAST
PL1937662T3 (pl) Sposób wytwarzania duloksetyny
IL190963A0 (en) Novel processes for the preparation of piperazinly and diazapanyl benzamide derivatives
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
HUP0401379A3 (en) Process for the preparation of risperidon
ZA200706203B (en) Processes and compounds for the preparation of substituted naphthylindole derivatives
HUP0500570A2 (en) Process for the preparation of (s)-(-)-amlodipine
EP1854844A4 (en) POLYANILINE CONTAINING COMPOSITION AND PROCESS FOR PRODUCING THE SAME
SI1732916T1 (sl) Postopek za pripravo alkoksikarbonilmetoksi-ciklopentanov